BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol. 2008;190:736-741. [PMID: 18287446 DOI: 10.2214/ajr.07.3115] [Cited by in Crossref: 94] [Cited by in F6Publishing: 14] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Emre T, Kiliçkesmez Ö, Büker A, İnal BB, Doğan H, Ecder T. Renal function and diffusion-weighted imaging: a new method to diagnose kidney failure before losing half function. Radiol Med 2016;121:163-72. [PMID: 26392392 DOI: 10.1007/s11547-015-0579-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
3 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
4 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
5 Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010;83:590-5. [PMID: 20413447 DOI: 10.1259/bjr/17689538] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
6 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
8 Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, Dame MK, Varani J. Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 2011;144:621-35. [PMID: 21484406 DOI: 10.1007/s12011-011-9041-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
9 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
10 Borrero CG, Mountz JM, Mountz JD. Emerging MRI methods in rheumatoid arthritis. Nat Rev Rheumatol 2011;7:85-95. [PMID: 21045791 DOI: 10.1038/nrrheum.2010.173] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
11 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
12 Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, Salama AD, Kalra PA. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010;5:484-489. [PMID: 20093350 DOI: 10.2215/cjn.06580909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
13 Elmholdt TR, Olesen AB, Jørgensen B, Kvist S, Skov L, Thomsen HS, Marckmann P, Pedersen M. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013;8:e82037. [PMID: 24349178 DOI: 10.1371/journal.pone.0082037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
14 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]